Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.49 |
| ▸ | F3 | P13726 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.46 |
| ▸ | STAT3 | P40763 | 3/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.46 |
| ▸ | RELA | Q04206 | 3/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.46 |
| ▸ | BACE1 | P56817 | 3/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.41 |
| ▸ | FOS | P01100 | 1/20 | 0.41 |
| ▸ | JUN | P05412 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2743884 | 1.00 | CYP1A2 (0.49) | CYP1A2CYP2D6CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL2744170 | 0.81 | CYP1A2 (0.46) | CYP1A2CYP2D6CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL2744177 | 0.81 | CYP1A2 (0.46) | CYP1A2CYP2D6CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL5598963 | 0.80 | F3 (0.66) | CYP1A2CYP2D6CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL5598966 | 0.80 | F3 (0.66) | CYP1A2CYP2D6CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL2743832 | 0.79 | CYP1A2 (0.61) | CYP1A2CYP2D6CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL2743834 | 0.79 | CYP1A2 (0.61) | CYP1A2CYP2D6CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL29606654 | 0.78 | F3 (0.63) | CYP1A2CYP2D6CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL1486859 | 0.76 | NPC1 (0.39) | CYP1A1CYP1B1MAPT | |
| SCHEMBL2743993 | 0.76 | NFKB1 (0.56) | CYP1A2CYP2D6ALOX5NFKB1STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10751330-B2 | Human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2020-08-25 | — | — | US | claimed |
| US-20200147061-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2020-05-14 | — | — | US | claimed |
| US-10092550-B2 | Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof | IONS PHARMACEUTICAL S.À R.L. (LU) | 2018-10-09 | — | — | US | claimed |
| US-20170042865-A1 | THERAPEUTIC COMPOSITIONS CONTAINING CURCUMIN, HARMINE, AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | IONS PHARMACEUTICAL S.À R.L. (LU) | 2017-02-16 | — | — | US | claimed |
| US-8178727-B2 | Bis(arylmethylidene)acetone compound, anti-cancer agent, carcinogenesis-preventive agent, inhibitor of expression of Ki-Ras, ErbB2, c-Myc and Cycline D1, β-catenin-degrading agent, and p53 expression enhancer | NATIONAL UNIVERSITY CORPORATION TOHOKU UNIVERSITY (JP) | 2012-05-15 | — | — | US | claimed |
| US-20100152493-A1 | BIS(ARYLMETHYLIDENE)ACETONE COMPOUND, ANTI-CANCER AGENT, CARCINOGENESIS-PREVENTIVE AGENT, INHIBITOR OF EXPRESSION OF Ki-Ras, ErbB2, c-Myc AND CYCLINE D1, BETA-CATENIN-DEGRADING AGENT, AND p53 EXPRESSION ENHANCER | SHIBATA, HIROYUKI (JP) | 2010-06-17 | — | — | US | claimed |
| US-12053440-B2 | Inhibition of COVID-19 virus by formulations containing curcumin, harmine, and isovanillin | ANKH LIFE SCIENCES LIMITED (IE) | 2024-08-06 | — | — | US | disclosed |
| US-20220193007-A1 | INHIBITION OF COVID-19 VIRUS BY MULTIPLE-COMPONENT FORMULATIONS | ANKH LIFE SCIENCES LIMITED (IE) | 2022-06-23 | — | — | US | disclosed |
| US-8178727-B2 | Bis(arylmethylidene)acetone compound, anti-cancer agent, carcinogenesis-preventive agent, inhibitor of expression of Ki-Ras, ErbB2, c-Myc and Cycline D1, β-catenin-degrading agent, and p53 expression enhancer | NATIONAL UNIVERSITY CORPORATION TOHOKU UNIVERSITY (JP) | 2012-05-15 | — | — | US | disclosed |
| US-20100152493-A1 | BIS(ARYLMETHYLIDENE)ACETONE COMPOUND, ANTI-CANCER AGENT, CARCINOGENESIS-PREVENTIVE AGENT, INHIBITOR OF EXPRESSION OF Ki-Ras, ErbB2, c-Myc AND CYCLINE D1, BETA-CATENIN-DEGRADING AGENT, AND p53 EXPRESSION ENHANCER | SHIBATA, HIROYUKI (JP) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152493-A1 | BIS(ARYLMETHYLIDENE)ACETONE COMPOUND, ANTI-CANCER AGENT, CARCINOGENESIS-PREVENTIVE AGENT, INHIBITOR OF EXPRESSION OF Ki-Ras, ErbB2, c-Myc AND CYCLINE D1, BETA-CATENIN-DEGRADING AGENT, AND p53 EXPRESSION ENHANCER | MYC, CCNE2, CCNE1 | CYP1A2 1717/4885CYP2D6 1871/4885CYP3A4 2309/4885 |
| US-20220193007-A1 | INHIBITION OF COVID-19 VIRUS BY MULTIPLE-COMPONENT FORMULATIONS | IDO2, IDO1, MAVS | CYP1A2 275/4885CYP2D6 626/4885CYP3A4 185/4885 |
| US-10751330-B2 | Human therapeutic agents | INMT, HNMT, HASPIN | CYP1A2 2166/4885CYP2D6 2367/4885CYP3A4 1778/4885 |
| US-20170042865-A1 | THERAPEUTIC COMPOSITIONS CONTAINING CURCUMIN, HARMINE, AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, CPT1A | CYP1A2 1194/4885CYP2D6 2218/4885CYP3A4 1136/4885 |
| US-10092550-B2 | Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof | INMT, HNMT, CPT1A | CYP1A2 1194/4885CYP2D6 2218/4885CYP3A4 1136/4885 |
| US-12053440-B2 | Inhibition of COVID-19 virus by formulations containing curcumin, harmine, and isovanillin | MAVS, IDO2, IDO1 | CYP1A2 362/4885CYP2D6 744/4885CYP3A4 287/4885 |
| US-20200147061-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | CYP1A2 2166/4885CYP2D6 2367/4885CYP3A4 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.